http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2371942-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9237fdf6dca9ac365fc5166858e7862 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-32 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-366 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-32 |
| filingDate | 2007-06-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2012-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e5a199d39a1fe9bcffd0a11bcb1b3d9a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_be80dafd17f5193f67dedc1143c2a9f7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8194baa6cc90b46afc75bd2b9108f156 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_521b7a70e9096d9797e7caa9fa05fa89 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83e6c5d1ec80fb65949cf33054548a6f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4863f403a4999a16447fa1d7d5094192 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_149fe4c7312b2e36c7c76cea0f39cb8e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fef00e7c073959694bd1b1656d6d794d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_30cda4bf02ded49fda81331ac9176ae0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3a0dfcca01520a63b2e76ed35053c1ed |
| publicationDate | 2012-01-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2371942-T3 |
| titleOfInvention | ANTITUMORIAL COMPOUNDS OF DIHIDROPIRAN-2-ONA. |
| abstract | A compound of general formula I in which R1 is selected from hydrogen, ORa, OCORa, OCOORa, NRaRb, NRaCORb and NRaC (NRa) NRaRb; each R2 and R3 is independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl and substituted or unsubstituted C2-C12 alkynyl; each R41, R42, R43, R44, R45, R46, R47 and R48 is independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl and substituted or unsubstituted C2-C12 alkynyl; each R5, R6 and R7 is independently selected from hydrogen, CORa, COORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl and substituted or unsubstituted C2-C12 alkynyl, or R5 and R48 together with the corresponding N and C atoms to which they are attached can form a substituted or unsubstituted heterocyclic group; each Ra and Rb is independently selected from hydrogen, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, substituted or unsubstituted C2-C12 alkynyl, substituted or unsubstituted aryl and substituted or unsubstituted heterocyclic group; and each dotted line represents an optional additional link; or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof. |
| priorityDate | 2006-06-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 321.